Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Deulorlatinib |
| Synonyms | |
| Therapy Description |
Deulorlatinib (TGRX-326) is a third-generation ALK and ROS1 inhibitor, which potentially inhibits growth of ALK or ROS1-positive tumors (PMID: 39551469). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Deulorlatinib | TGRX-326|TGRX326|TGRX 326 | ALK Inhibitor 33 ROS1 Inhibitor 22 | Deulorlatinib (TGRX-326) is a third-generation ALK and ROS1 inhibitor, which potentially inhibits growth of ALK or ROS1-positive tumors (PMID: 39551469). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ALK rearrange | lung non-small cell carcinoma | sensitive | Deulorlatinib | Phase I | Actionable | In a Phase I/Ib trial, Deulorlatinib (TGRX-326) treatment demonstrated safety in non-small cell lung cancer patients harboring an ALK rearrangement and led to an objective response rate (ORR) of 71.4% (10/14) and disease control rate (DCR) of 100% in Xalkori (crizotinib)-pretreated patients, an ORR of 87.9% (29/33) and DCR of 97.0% (32/33) in TKI-naive patients, and an ORR of 38.1% (37/97) and DCR of 81.4% (79/97) in patients pre-treated with second-generation TKIs (PMID: 39551469; NCT05441956). | 39551469 |
| EML4 - ALK | Advanced Solid Tumor | sensitive | Deulorlatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Deulorlatinib (TGRX-326) inhibited viability of cells expressing EML4-ALK in culture (PMID: 39551469). | 39551469 |
| EML4 - ALK ALK L1196M | Advanced Solid Tumor | sensitive | Deulorlatinib | Preclinical | Actionable | In a preclinical study, Deulorlatinib (TGRX-326) inhibited viability of cells expressing EML4-ALK and ALK L1196M in culture and inhibited tumor growth in a transplant model (PMID: 39551469). | 39551469 |
| EML4 - ALK ALK G1202R | Advanced Solid Tumor | sensitive | Deulorlatinib | Preclinical | Actionable | In a preclinical study, Deulorlatinib (TGRX-326) inhibited viability of cells expressing EML4-ALK and ALK G1202R in culture and inhibited tumor growth in a transplant model (PMID: 39551469). | 39551469 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|
CKB BOOST